Imaging biomarkers as surrogate endpoints for drug development

ISSN： 1619-7070

Source： European Journal of Nuclear Medicine and Molecular Imaging, Vol.33, Iss.1, 2006-07, pp. : 6-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions

By Rudin Markus

European Radiology, Vol. 17, Iss. 10, 2007-10 ,pp. : 2441-2457

Springer Publishing Company

Access to resources Recommend Favorite

Development and Use of Biomarkers in Oncology Drug Development

By FLOYD EUGENIA MCSHANE TERESA

Toxicologic Pathology, Vol. 32, Iss. 1, 2004-03 ,pp. : 106-115

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Quantitative Imaging Biomarker Ontology (QIBO) for Knowledge Representation of Biomedical Imaging Biomarkers

By Buckler Andrew

Journal of Digital Imaging, Vol. 26, Iss. 4, 2013-08 ,pp. : 630-641

Springer Publishing Company

Access to resources Recommend Favorite

Beyond haematuria in uro oncology: imaging biomarkers lag behind needs

By Lucignani Giovanni

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, Iss. 1, 2009-01 ,pp. : 152-157

Springer Publishing Company

Access to resources Recommend Favorite

FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma

By Paidpally Vasavi Chirindel Alin Lam Stella Agrawal Nishant Quon Harry Subramaniam Rathan M

Imaging in Medicine, Vol. 4, Iss. 6, 2012-12 ,pp. : 633-647

Future Medicine

Access to resources Recommend Favorite